ClinicalTrials.Veeva

Find clinical trials for Triple Negative Breast Cancer in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near London, England, GBR:

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common subtype of breast cancer...

Enrolling
Locally Advanced Breast Cancer
HER2-positive Breast Cancer
Drug: Avelumab
Drug: Palbociclib

Phase 1

Royal Marsden NHS Foundation Trust

London, United Kingdom and 7 other locations

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

Leicester, United Kingdom and 44 other locations

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Enrolling
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Datopotamab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

London, United Kingdom and 46 other locations

A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients (c-TRAK-TN)

residual disease following patients standard primary treatment for triple negative breast cancer, and will assess...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Pembrolizumab

Phase 2

Institute of Cancer Research, United Kingdom

London, United Kingdom and 16 other locations

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer

PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patien...

Enrolling
Breast Neoplasm
Drug: Durvalumab
Drug: AZD6738

Phase 2

Institute of Cancer Research, United Kingdom

London, United Kingdom and 8 other locations

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)

The purpose of this study is to find out how effective the combination of crizotinib and fulvestrant is in shrinking lobular breast cancer...

Active, not recruiting
Gastric Cancer
Lobular Breast Carcinoma
Drug: Crizotinib Oral Capsule [Xalkori]
Drug: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]

Phase 2

Royal Marsden NHS Foundation Trust

London, United Kingdom and 4 other locations

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC (BARBICAN)

non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Paclitaxel
Drug: Doxorubicin

Phase 2

Queen Mary University of London

London, United Kingdom

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Niraparib
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

London, United Kingdom and 226 other locations

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer (PARTNER)

This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement ...

Enrolling
Breast Cancer
Drug: Paclitaxel and Carboplatin
Drug: Olaparib

Phase 2, Phase 3

NHS Foundation Trust
NHS Foundation Trust

London, United Kingdom and 29 other locations

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)

the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capecitabine
Drug: Atezolizumab

Phase 3

Roche
Roche

London, United Kingdom and 137 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems